Update on partial response in depression

Journal of Clinical Psychiatry

Volumn 70, Issue SUPPL. 6, 2009, Pages 4-9

  Thase, Michael E ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; APLENZIN; ARIPIPRAZOLE; BUSPIRONE; CITALOPRAM; FLUOXETINE; FLUOXETINE PLUS OLANZAPINE; IMIPRAMINE; LITHIUM; LITHIUM CARBONATE; METHYLPHENIDATE; MODAFINIL; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; PSYCHOSTIMULANT AGENT; QUETIAPINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; UNCLASSIFIED DRUG; VENLAFAXINE;

AKATHISIA; ANXIETY DISORDER; ARTICLE; CHRONICITY; CLINICAL PRACTICE; CLINICAL TRIAL; COMORBIDITY; DEPRESSION; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; HAMILTON SCALE; HUMAN; MAJOR DEPRESSION; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; PSYCHOMETRY; PSYCHOTHERAPY; REMISSION; RESTLESSNESS; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; SYMPTOMATOLOGY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; WATCHFUL WAITING; WEIGHT GAIN;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; ANXIETY DISORDERS; CHRONIC DISEASE; CITALOPRAM; COMORBIDITY; DEPRESSIVE DISORDER, MAJOR; DRUG THERAPY, COMBINATION; HUMANS; LITHIUM COMPOUNDS; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 72549089426     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.8133su1c.01     Document Type: Article

References (20)

1. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder. 2nd edition. http://www. psychiatryonline.com/pracGuide/loadGuidelinePdf.aspx?file=MDD2e-05-15-06. Accessed May 20, 2009.
2. Reesal RT, Lam RW, for the CANMAT Depression Work Group. Clinical guidelines for the treatment of depressive disorders, II: principles of management. Can J Psychiatry. 2001;46(suppl 1):21s-28s. PubMed
3. Judd LL, Paulus MJ, Schettler PJ, et al. Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness? Am J Psychiatry. 2000;157(9):1501-1504. PubMed doi:10.1176/appi.ajp.157.9.1501
4. Miller IW, Keitner GI, Schatzberg AF, et al. The treatment of chronic depression, III: psychosocial functioning before and after treatment with sertraline or imipramine. J Clin Psychiatry. 1998;59(11):608-619. PubMed
5. Murphy JM, Monson RR, Olivier DC, et al. Affective disorders and mortality: a general population study. Arch Gen Psychiatry. 1987;44(5):473-480. PubMed
6. Judd LL, Akiskal HS, Paulus MP. The role and clinical significance of subsyndromal depressive symptoms (SSD) in unipolar major depressive disorder. J Affect Disord. 1997;45(1-2):5-18. PubMed doi:10.1016/S0165-0327(97)00055-4
7. Thase ME. Introduction: defining remission in patients treated with antidepressants. J Clin Psychiatry. 1999;60(suppl 22):3-6. PubMed
8. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163(1):28-40. PubMed doi:10.1176/appi.ajp.163.1.28
9. Thase ME. Evaluating antidepressant therapies: remission as the optimal outcome. J Clin Psychiatry. 2003;64(suppl 13):18-25. PubMed
10. Rush AJ, Trivedi JH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905-1917. PubMed doi:10.1176/appi.ajp.163.11.1905
11. Fava M, Rush AJ, Alpert JE, et al. Difference in treatment outcome in patients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry. 2008;165(3):342-351. PubMed doi:10.1176/appi.ajp.2007.06111868 (Pubitemid 351704490)
12. Judd LL, Akiskal HS, Maser JD, et al. Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Disord. 1998;50(2-3):97-108. PubMed doi:10.1016/S0165- 0327(98)00138-4
13. Crossley NA, Bauer M. Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials. J Clin Psychiatry. 2007;68(6):935-940. PubMed
14. Aronson R, Offman HJ, Joffe RT, et al. Triiodothyronine augmentation in the treatment of refractory depression: a meta-analysis. Arch Gen Psychiatry. 1996;53(9):842-848. PubMed
15. Nierenberg AA, Fava M, Trivedi MH, et al. A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry. 2006;163(9):1519-1530. PubMed doi:10.1176/appi.ajp.163.9.1519 (Pubitemid 44465751)
16. Fava M, Thase ME, DeBattista C. A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. J Clin Psychiatry. 2005;66(1):85-93. PubMed
17. Patkar AA, Masand PS, Pae CU, et al. A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression. J Clin Psychopharmacol. 2006;26(6):653-656. PubMed doi:10.1097/01.jcp.0000246212.03530. fd
18. Shelton RC, Tollefson GD, Tohen M, et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry. 2001;158(1):131-134. PubMed doi:10.1176/appi.ajp.158.1.131 (Pubitemid 32047260)
19. Thase ME, Corya SA, Osuntokun O, et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. J Clin Psychiatry. 2007;68(2):224-236. PubMed (Pubitemid 46362643)
20. Berman RM, Marcus RN, Swanink R, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2007;68(6):843-853. PubMed (Pubitemid 47015482)